Welcome to our dedicated page for NEOGENOMICS SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeoGenomics, Inc. filings document the regulatory record of an oncology diagnostics company whose common stock trades on Nasdaq under the symbol NEO. Form 8-K reports furnish quarterly and annual operating results, preliminary financial information, press release exhibits, and Regulation FD disclosures tied to the company’s clinical testing and diagnostic services business.
The company’s proxy materials cover board structure, director matters, executive compensation, equity awards, pay-versus-performance disclosures and annual meeting governance. Other material-event filings describe officer transitions, board appointments and resignations, and registered security information, including common stock par value and exchange listing details.
NeoGenomics, Inc. reported strong Q2 2026 growth with total revenue of $202 million, up 11% year over year. Clinical services revenue rose 14% to $187 million, supported by 26% NGS growth. Gross profit increased to $91.9 million with gross margin at 45.6% and adjusted gross margin at 48.1%. Operating expenses fell 19%, aided by the absence of prior-year impairment charges, narrowing the operating loss to $9.8 million.
GAAP net income was $2.2 million versus a $45.1 million loss a year earlier, including an $11.2 million gain on extinguishment of debt; adjusted net income reached $6.7 million and adjusted EBITDA grew 36% to $14.5 million. The company refinanced its convertible notes through a $316 million private offering of 0.75% notes due 2032, repurchased $276 million of 0.25% notes due 2028, entered capped call transactions to limit conversion dilution, and bought back $25 million of common stock, ending the quarter with $145.5 million of cash and equivalents. Updated 2026 guidance calls for revenue of $802–$806 million, net loss of $34–$42 million, and adjusted EBITDA of $56–$58 million.
NeoGenomics, Inc. filed an amendment to correct date references in a prior current report, changing erroneous “June 20, 2026” mentions in Items 7.01 and 8.01 to the correct date, July 20, 2026. The amendment restates those items but does not update any other prior disclosure.
The company had voluntarily conducted an internal investigation into the compliance of certain consulting and service agreements with federal healthcare laws and regulations and notified the Office of Inspector General of the U.S. Department of Health and Human Services in November 2021. On July 20, 2026, NeoGenomics finalized a civil settlement with the U.S. Department of Justice, acting on behalf of OIG-HHS, resolving the government’s investigation concerning consulting services provided to certain health care providers. Under the settlement, NeoGenomics will pay $9,813,260. As of March 31, 2026, it had accrued a reserve of $11.2 million for potential damages and liabilities. The settlement agreement states it is neither an admission of liability by the company nor a concession by the United States that its claims are not well founded.
NeoGenomics, Inc. reported that it finalized a civil settlement with the U.S. Department of Justice, acting on behalf of OIG-HHS, resolving a government investigation into consulting services provided to certain health care providers under its Laboratory Collaboration Initiative program.
The company had voluntarily conducted an internal review of compliance with federal healthcare laws and self-disclosed the matter to OIG-HHS in November 2021. Under the settlement, NeoGenomics agreed to pay $9,813,260 plus interest at 4.250% per annum from January 16, 2026. As of March 31, 2026, it had accrued a reserve of $11.2 million for potential damages and liabilities associated with this investigation. The settlement agreement states it is neither an admission of liability by NeoGenomics nor a concession by the United States regarding its claims.
NEOGENOMICS INC director Carolyn S. Starrett reported receiving new equity awards. On 2026-06-23, she was granted 14,125 Restricted Stock Units, each representing one share of common stock when vested. She was also granted stock options for 9,784 shares of common stock at an exercise price of $11.20 per share, expiring on 2036-06-01. A footnote states that once vested, the common shares underlying these awards are not subject to expiration.
NEOGENOMICS INC director Carolyn S. Starrett filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The filing shows no reported transactions or holdings at this time, indicating it is an initial disclosure establishing her status as a reporting person.
NeoGenomics, Inc. filed a current report announcing that its Board of Directors increased in size from nine to ten members and appointed Carolyn S. Starrett as a new director, effective immediately. She will serve until the 2027 annual meeting of stockholders and then until a successor is elected and qualified.
Starrett brings more than 25 years of experience in data, technology, and oncology, including executive roles at Flatiron Health, where she served as CEO and Board Director, and prior board service at Foundation Medicine. NeoGenomics highlights her expertise in real-world data, AI, and analytics to support its oncology diagnostics and precision medicine strategy.
NeoGenomics, Inc. completed a private offering of $275.0 million of 0.75% Convertible Senior Notes due 2032, and an additional $41.25 million from the purchasers’ option, for total notes of $316.25 million in senior unsecured debt.
The notes carry 0.75% annual interest, payable semiannually, and mature on July 1, 2032, with conversion initially at 70.6140 shares per $1,000 (about $14.16 per share), a 35% premium to the $10.49 share price on June 16, 2026. NeoGenomics entered into capped call transactions with a $20.98 cap and paid about $28.7 million for them to help limit dilution on conversion.
The company relied on private offering exemptions and may issue up to 30,147,733 shares upon conversion, based on the initial maximum conversion rate. Concurrently, it repurchased approximately $276.0 million principal of 0.25% convertible notes due 2028 for about $263.19 million and arranged up to $25.0 million of share repurchases at $10.49 per share.
NeoGenomics director Lynn A. Tetrault reported an open-market sale of 5,307 shares of Common Stock at $11.10 per share on June 15, 2026. After this transaction, she directly holds 86,115 Common shares.
She also indirectly holds 7,000 Common shares through a Lynn Tetrault Rollover IRA. In addition, she has 15,970 Restricted Stock Units tied to Common Stock and multiple stock option grants covering various numbers of underlying shares with exercise prices ranging from $8.10 to $41.76 and expirations between 2026 and 2036.
NeoGenomics, Inc. is privately offering $275 million of 0.75% convertible senior notes due 2032 to qualified institutional buyers, with an additional $41.25 million option for initial purchasers. The notes are convertible into cash, common stock, or a mix, at the company’s election.
The initial conversion rate is 70.6140 shares per $1,000, implying a conversion price of about $14.16 per share, a 35% premium to the $10.49 last sale price. NeoGenomics expects net proceeds of about $266.15 million, or $306.16 million if the option is fully exercised.
The company plans to spend about $25 million on capped call transactions with a $20.98 cap price, repurchase $276 million principal of 0.25% convertible notes due 2028 for about $263.19 million, and may repurchase up to $25 million of common stock, using any remaining proceeds for general corporate purposes.
NeoGenomics, Inc. plans a private offering of $275 million aggregate principal amount of convertible senior notes due 2032, limited to investors reasonably believed to be qualified institutional buyers. An option may allow initial purchasers to buy up to an additional $41.25 million of notes.
The notes will be senior unsecured obligations, maturing on July 1, 2032, with semi-annual interest and investor conversion rights. NeoGenomics may redeem the notes for cash after July 6, 2029 if its share price meets a 130% conversion-price threshold. The company plans capped call transactions and expects to use proceeds to help fund these, repurchase a portion of its 0.25% convertible notes due 2028, repurchase up to $25 million of common stock from certain note purchasers, and for general corporate purposes.